With more drugmakers outsourcing more trials to contract research organizations, few should be surprised that the CRO sector is generating investor interest. The attention-grabbing deal announced this week in which two private equity firms – Carlyle Group and Hellman & Friedman – agreed to pay $3.9 billion in cash to buy Pharmaceutical Product Development is no random bet.
http://www.forbes.com/sites/edsilverman/2011/10/04/why-contract-research-organizations-are-so-hot/